Bioequivalence and Bioavailability Forum

Main page Policy Latest Posts Abbreviations

Amlodipine/Valsartan [Design Issues]

posted by Kumarnaidu2 – India, 2023-12-07 03:42 (282 d 19:05 ago) – Posting: # 23786
Views: 1,826

Hello dshah

❝ I believe that for Amlodipine the ISCV would be LT 30%, so by default the ABE calculation becomes applicable. So what advantages would be there to have such statistical plan?

❝ Further- analysis of Amlodipine would be required to link any AE for last period. And if it is analyzed, what can be the justification for not using in PK stat?

The reported ISCV for Amlodipine is around 9 to 12%.

Complete thread:

Amlodipine/Valsartan Bebac user 2023-09-09 06:34 [Design Issues]
- Amlodipine/Valsartan Helmut 2023-09-12 06:48
  - Amlodipine/Valsartan Kumarnaidu2 2023-12-06 09:36
    - Amlodipine/Valsartan dshah 2023-12-06 16:49
      - Amlodipine/ValsartanKumarnaidu2 2023-12-07 02:42
    - Use all data and avoid the partial replicate design for the FDA Helmut 2023-12-07 09:01

Admin contact
23,225 posts in 4,879 threads, 1,652 registered users;
36 visitors (0 registered, 36 guests [including 9 identified bots]).
Forum time: 23:48 CEST (Europe/Vienna)

We absolutely must leave room for doubt
or there is no progress and no learning.
There is no learning without having to pose a question.
And a question requires doubt.
People search for certainty.
But there is no certainty. Richard Feynman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC

Ing. Helmut Schütz